QT prolongation with anticancer drugs: a multimodal issue - Authors' reply
- PMID: 36455572
- DOI: 10.1016/S1470-2045(22)00695-7
QT prolongation with anticancer drugs: a multimodal issue - Authors' reply
Conflict of interest statement
NPvE has received research grants for Radboudumc from Astellas Pharma, Janssen-Cilag, Ipsen, KWF, and ZonMW, and has received payments for Radboudumc from Sanofi, Bayer, and Pfizer. ELG and EJS declare no competing interests.
Comment on
-
The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview.Lancet Oncol. 2022 Sep;23(9):e406-e415. doi: 10.1016/S1470-2045(22)00221-2. Lancet Oncol. 2022. PMID: 36055309 Review.
-
QT prolongation with anticancer drugs: a multimodal issue.Lancet Oncol. 2022 Dec;23(12):e522. doi: 10.1016/S1470-2045(22)00622-2. Lancet Oncol. 2022. PMID: 36455571 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources